Short Interest in Evaxion Biotech A/S (NASDAQ:EVAX) Declines By 40.8%

Evaxion Biotech A/S (NASDAQ:EVAX) saw a large decrease in short interest in July. As of July 15th, there was short interest totalling 52,100 shares, a decrease of 40.8% from the June 30th total of 88,000 shares. Based on an average daily volume of 37,600 shares, the short-interest ratio is currently 1.4 days.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. HC Wainwright reissued a “buy” rating and set a $14.00 price target on shares of Evaxion Biotech A/S in a research report on Tuesday, June 4th. LADENBURG THALM/SH SH raised Evaxion Biotech A/S from a “neutral” rating to a “buy” rating and set a $8.00 target price on the stock in a research report on Tuesday, April 2nd.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Evaxion Biotech A/S stock. LM Advisors LLC bought a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm bought 337,336 shares of the company’s stock, valued at approximately $231,000. LM Advisors LLC owned approximately 8.90% of Evaxion Biotech A/S as of its most recent SEC filing. Institutional investors own 11.04% of the company’s stock.

Evaxion Biotech A/S Stock Performance

Shares of NASDAQ:EVAX traded up $0.11 on Friday, hitting $3.02. The company’s stock had a trading volume of 7,882 shares, compared to its average volume of 318,091. Evaxion Biotech A/S has a 12 month low of $2.26 and a 12 month high of $13.82. The company has a market capitalization of $16.34 million, a price-to-earnings ratio of -0.68 and a beta of -0.28. The stock’s 50-day moving average is $3.21 and its two-hundred day moving average is $3.98.

Evaxion Biotech A/S (NASDAQ:EVAX) last released its quarterly earnings results on Tuesday, May 28th. The company reported $0.03 earnings per share (EPS) for the quarter. The business had revenue of $0.05 million during the quarter. Equities analysts expect that Evaxion Biotech A/S will post -0.1 earnings per share for the current fiscal year.

About Evaxion Biotech A/S

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase 1/2a trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy that is in pre-clinical stage for the treatment of various cancers.